Roche licenses Rona's ALK7 RNAi obesity drug in deal worth up to $1.16B

Roche agreed on October 13, 2026, to license an experimental obesity drug from Shanghai-based Rona Therapeutics, gaining exclusive worldwide rights to a candidate that has not been identified by name and whose stage of development was not disclosed ^[1][2][3]. The maximum value of the deal is $1.16 billion ^[1][3].

The Swiss drugmaker will pay up to $100 million in upfront and near-term milestone payments. Rona is also eligible for up to $1.06 billion in longer-term milestone payments, plus tiered royalties on global net sales ^[1][2][3]. Those figures are ceilings: the $1.06 billion is tied to reaching development, regulatory and commercial goals, so the final amount depends on whether those targets are hit ^[3].

The licensed candidate is an RNA interference (RNAi) therapy, a type of drug that silences genes, aimed at ALK7, short for activin receptor-like kinase 7 ^[2][3]. ALK7 is a protein encoded by the ACVR1C gene, found mainly in fat tissue and involved in lipid metabolism ^[2]. Human genetic studies have linked ALK7 variants to smaller waist-to-hip ratios, a measure of abdominal obesity, and blocking ALK7 signaling makes mice resistant to obesity ^[2].

Rona chief executive Stella Shi said the program reflects the need for "mechanisms that can improve the quality and durability of weight loss," calling ALK7 "a compelling obesity and metabolic disease target with the potential to directly address adipose tissue biology" ^[2]. The candidate uses Rona's extrahepatic delivery platform ^[2]. Rona's public pipeline lists two preclinical obesity programs against undisclosed targets, and none of its assets with disclosed targets work on ALK7 ^[2]. The specific molecule Roche licensed is therefore not yet public.

Roche is not the only company pursuing ALK7. Arrowhead Pharmaceuticals reported in January a 14.1% placebo-adjusted reduction in visceral fat eight weeks after patients received one dose of its candidate ^[2]. Alnylam began a clinical trial of an ALK7 candidate in March and has said phase 1 data are expected in the second half of 2026 ^[2]. GSK paid China's SiranBio $55 million in May for a phase 1 ALK7 candidate ^[2]. Novo Nordisk chief scientific officer Martin Holst Lange said at an investor day last month that the company has "a number of assets" against ALK7, with its most advanced candidate entering the clinic this year ^[2].

For Roche, the license adds to a portfolio built through deals. The company has said it aims to become a "top three" obesity company, and it entered the field through the $2.7 billion buyout of Carmot Therapeutics, followed by agreements with Hanmi Pharm and Zealand Pharma ^[2]. Results have been mixed; one muscle-sparing obesity antibody was dropped after a failed interim analysis ^[2]. In September, Roche reported positive mid-stage data for its obesity and diabetes candidate enicepatide ^[1].

Why it matters for patients

Nothing in this agreement changes what is available today. The Rona candidate is investigational and has not been approved ^[1][3], and the obesity drug market is dominated by Eli Lilly and Novo Nordisk ^[1]. No medicine that targets ALK7 has been approved, and no human efficacy or safety data for the licensed Rona molecule have been disclosed ^[2].

If the approach works, it could offer a different route to weight loss. Targeting the ALK7 pathway could in theory reduce fat deposits while preserving lean mass, and such drugs could be used alone or combined with incretin mimetics such as GLP-1 receptor agonists ^[2]. The only human result disclosed so far is Arrowhead's single-dose visceral fat finding ^[2]. Long-term effects, side effects, dosing, how much weight people might lose and how long any loss lasts have not been reported for this class.

The financial terms are not a measure of medical benefit. The $1.16 billion is a maximum tied to milestones and sales, not money already paid ^[1][3].

What happens next

Roche and Rona did not disclose a timeline for the licensed program, and no start date for human testing has been reported ^[2]. Novo Nordisk said its most advanced ALK7 candidate will enter the clinic this year ^[2]. Alnylam has said phase 1 data for its ALK7 candidate are expected in the second half of 2026 ^[2]. GSK's ALK7 candidate, licensed from SiranBio, is in phase 1 ^[2]. No late-stage results have been reported for any ALK7 program.